Clinical, Molecular, and Computational Analysis Showed a Novel Homozygous Mutation Among the Substrate-Binding Site of ARSA Protein in Consanguineous Family with Late-Infantile MLD

J Mol Neurosci. 2018 Sep;66(1):17-25. doi: 10.1007/s12031-018-1141-z. Epub 2018 Aug 6.

Abstract

Metachromatic leukodystrophy (MLD) is a neurodegenerative disorder characterized by progressive demyelination resulting from impaired degradation and thus the accumulation of cerebroside-3-sulfate (sulfatide). It is caused by the deficiency of arylsulfatase A (ARSA) enzyme which is encoded by the ARSA gene. The present study reports the clinical, molecular, and bioinformatic investigation of three patients belonging to a consanguineous family with late-infantile MLD disorder. The results revealed a novel homozygous missense mutation c.699C>A (p.His231Gln) in exon 4 of ARSA gene in the three patients inherited from their heterozygous parents. Interestingly, this novel mutation is the second mutation identified in the substrate-binding site of ARSA protein and it was classified as damaging and deleterious by several bioinformatics tools. The c.699C>A (p.His231Gln) leads to changes in the pre-mRNA secondary structure and in the ARSA protein 3D structure with a significant root mean square deviation value which could probably affect its stability and function.

Keywords: ARSA gene; Arylsulfatase A; Late-infantile MLD.

Publication types

  • Case Reports

MeSH terms

  • Binding Sites
  • Cerebroside-Sulfatase / chemistry
  • Cerebroside-Sulfatase / genetics*
  • Cerebroside-Sulfatase / metabolism
  • Child, Preschool
  • Consanguinity
  • Exons
  • Female
  • Heterozygote
  • Homozygote
  • Humans
  • Infant
  • Leukodystrophy, Metachromatic / genetics*
  • Leukodystrophy, Metachromatic / pathology
  • Male
  • Molecular Dynamics Simulation
  • Mutation, Missense*
  • Pedigree
  • Protein Binding

Substances

  • Cerebroside-Sulfatase